EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Update Il y a 4 ans
Reference: NCT00470678

Woman and Man

Extract

This study will evaluate efficacy and safety for monthly ranibizumab 0.5 mg intravitreal injections in Asian patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.


Inclusion criteria

  • Choroidal Neovascularization ,Age-related macular degeneration

Links